The roadmap by these 13 drug firms follows the Industry Declaration signed in January 2016 at the World Economic Forum by more than 100 companies and trade associations, the companies said in a joint statement.
The other companies in the alliance include global majors such as Johnson & Johnson, Novartis, Pfizer, Sanofi and AstraZeneca.
The four key commitments on reducing antimicrobial resistance are: reducing the environmental impact from the production of antibiotics; ensuring antibiotics are used only by patients who need them; improving access to current and future antibiotics, vaccines and diagnostics and exploring new opportunities for open collaborations between industry and the public sector, the statement said.
"I strongly encourage the collaboration between industry and governments, as it is only together that we can tackle antimicrobial resistance."
Also Read
"We will only overcome this challenge through effective collaboration between governments, NGOs and the private sector," he added.
Antimicrobial resistance (AMR) is the natural process by which bacteria and other microbes develop resistance to the drugs commonly used to treat infections. Antimicrobials include antibiotics (which act only on bacteria), antivirals, antiparasitics and antifungals.
Disclaimer: No Business Standard Journalist was involved in creation of this content